Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: section IIb final results In summary, even though the scientific impact of tucidinostat for that treatment of PTCL has actually been elucidated, further mechanistic examine and biomarker identification for client stratification must be illustrated in the future. https://campbellw554vgs8.wikicommunications.com/user